 |
11 Diseases |  |
24 Trials |
|
24 Trials |  |
1081 News |  |
| «12345678910111213...1314» |
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Baseline Predictors of an Enhanced Response to Tezepelumab Treatment Versus Placebo: Results From the Phase 3 NAVIGATOR Study (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6025;
P3
The strongest baseline predictors of an enhanced reduction in exacerbations with tezepelumab versus placebo were prior exacerbations, lung function and FeNO levels. These findings further support the benefits of tezepelumab in a broad range of patients with severe, uncontrolled asthma and may identify patients likely to have the greatest treatment response.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab Efficacy by SNOT-22 Domain Scores in Patients With Severe, Uncontrolled Asthma and Comorbid Nasal Polyps in the Phase 3 Navigator Study (Walter E. Washington Convention Center, Room 103 A-B (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_6022;
P3
Numerical reductions were observed across all domains, with the greatest reductions seen in nasal, sleep, and function domains. These results demonstrate the efficacy of tezepelumab in improving rhinosinusitis symptoms in patients with severe, uncontrolled asthma and a history of NP.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
First-in-class Inhalable Anti-TSLP Single Domain Antibody With Therapeutic Potential in Asthma Treatment (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_4607;
Given its great potency during in vitro and in vivo efficacy study, and the good safety profile in the non-clinical GLP repeat dose toxicity study, LQ043H is a very promising candidate for asthma treatment. In addition, LQ043H is now under clinical investigation in China.
- Corticosteroid-sparing Effect of Biologics in Patients With Allergic Bronchopulmonary Aspergillosis (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_4532;
Biologic therapy may reduce or eliminate the need for chronic corticosteroid therapy in patients with ABPA. Further work is needed to establish the relative efficacy of different biologics and identify which patients are most likely to benefit from biologic therapy.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
SUNRISE: A Phase 3, Parallel-group Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing OCS Use in OCS-dependent Patients With Severe Asthma (Walter E. Washington Convention Center, Area A, Hall C (Lower Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_4511;
P3
Further work is needed to establish the relative efficacy of different biologics and identify which patients are most likely to benefit from biologic therapy. SUNRISE will evaluate the efficacy and safety of tezepelumab compared with placebo in reducing maintenance OCS dose while maintaining asthma control in patients with severe, OCS-dependent asthma.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Prior Omalizumab Use: A Post Hoc Analysis of the Phase 3 Navigator Study (Walter E. Washington Convention Center, West Salon G-I (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_3878;
P3
Tezepelumab reduced the AAER compared with placebo in patients with severe, uncontrolled asthma irrespective of prior omalizumab use. These results further demonstrate the efficacy of tezepelumab in a broad range of patients with severe, uncontrolled asthma, including those who previously received omalizumab.
- The Role of Biologics in Decreasing Asthma Exacerbation Rate: A Systematic Review and Meta-analysis (Walter E. Washington Convention Center, Room 151 B (Street Level)) - Mar 25, 2023 - Abstract #ATS2023ATS_3492;
Monoclonal antibodies targeting the Interleukin (IL)-5 pathway (Mepolizumab, Rezlizumab, Benralizumab), IL-4 receptor inhibitor (Dupilumab), Thymic stromal lymphopoietin inhibitor (Tezepelumab), IL-13 inhibitor (Tralinkinumab), IL-23 inhibitor (Risankizumab), and IL-33 inhibitor, (Astegolimab) have been studied in randomized controlled trials (RCTs)...Two RCTs compared Reslizumab to placebo, random effects standard difference of means was -0.359 (confidence interval -0.259 to -0.140, p value <0.0001)... Biologic agents have shown to significantly decrease the rate of annual asthma exacerbation rate compared to placebo.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enhancing Adoption of New Targeted Agents and Empowering Patients With Severe Asthma: The Role of Tethered Education for Health Care Providers and Patients (Walter E. Washington Convention Center, Room 209 A-C (Level 2)) - Mar 25, 2023 - Abstract #ATS2023ATS_2916;
Data support the positive impacts of tethered education for HCPs and patients, preparing both for the evolving management of severe asthma and empowering patients to engage in treatment decision-making. Findings also highlight the need for continuing education to both groups on the individualization of therapy, and for patients to further empower them to express their treatment goals and voice their satisfaction with treatment.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Serum TSLP Levels in Asthma - Relationship to Type 2 and Non-Type 2 Biomarkers (Walter E. Washington Convention Center, Room 201 (Level 2)) - Mar 25, 2023 - Abstract #ATS2023ATS_2090;
Serum TSLP levels are increased in a subset of patients with asthma, and serum TSLP correlates with blood and sputum eosinophilia. Serum TSLP is not associated with biomarkers of metabolic asthma.
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion date, Trial primary completion date: PASSAGE: Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (clinicaltrials.gov) - Mar 24, 2023
P4, N=400, Recruiting, Sponsor: AstraZeneca
Serum TSLP is not associated with biomarkers of metabolic asthma. Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Jul 2025
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. (Pubmed Central) - Mar 13, 2023
Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Mar 2024 --> Jul 2025 No abstract available
- Evidence Gaps in Evaluating Comparative Effectiveness, Safety, and Cost-Effectiveness of Biologics in Health Technology Assessment (HTA) Submissions for the Treatment of Severe Asthma () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1628;
Our study underscored the significant gap in clinical data to evaluate comparative effectiveness, safety, and cost-effectiveness among biologics in severe asthma. Further research is warranted to design a large, pragmatic trial comparing all available drugs to determine the clinically important differences and identify subgroups of patients who are likely to benefit from a specific biologic therapy.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Patient Characteristics, Treatment Patterns, and Outcomes Among Early Tezepelumab Users: An Early View Claims Data Study () - Mar 9, 2023 - Abstract #ISPOR2023ISPOR_1073;
Initial users of tezepelumab were predominantly older, female patients, with a high burden of respiratory comorbidities, consistent with what would be expected for a population of uncontrolled severe asthma patients. Future studies assessing outcomes following tezepelumab treatment are planned.
- || Review, Journal: Biologics in the treatment of asthma in children and adolescents. (Pubmed Central) - Mar 7, 2023
The choice of a biologic agent follows a careful assessment of other factors that contribute to uncontrolled asthma and includes biomarkers of blood eosinophils, fractional exhaled nitric oxide, allergic sensitization, and IgE levels. This review focuses on the underlying pathophysiology of childhood asthma, an approach to phenotyping patients, and the efficacy, safety, and use of biologics in children and adolescents with severe asthma.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Journal, HEOR, Cost-effectiveness, Cost effectiveness: The Influence of US Drug Price Dynamics in Cost Effectiveness Analyses of Biologics. (Pubmed Central) - Mar 7, 2023
Two biologic treatment cases incorporating price dynamics in cost-effectiveness analyses had varied impacts on the cost-effectiveness ratio depending on the magnitude of pre-LOE price increase and post-LOE price decrease and whether the LOE also affected the comparator. Yearly price increase magnitude during the period of exclusivity, among other factors, may counterbalance the effects of lower post-LOE intervention prices.
- | Retrospective data, Journal: Comparative Efficacy of Tezepelumab to Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-analysis. (Pubmed Central) - Mar 7, 2023
Yearly price increase magnitude during the period of exclusivity, among other factors, may counterbalance the effects of lower post-LOE intervention prices. In individuals with eosinophilic asthma, tezepelumab and dupilumab were associated with greater improvements (although below clinical thresholds) in exacerbation rates and lung function than benralizumab or mepolizumab.
- | Journal: Mapping knowledge structure and research of the biologic treatment of asthma: A bibliometric study. (Pubmed Central) - Mar 3, 2023
This study systematically uncovers a holistic picture of existing literature related to the biologic treatment of asthma over the past 20 years. We consulted scholars in order to understand key information in this field from the perspective of bibliometrics, which we believe may greatly facilitate future research in this field.
- | Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: New Concepts in Barrier Dysfunction in CRSwNP and Emerging Roles of Tezepelumab and Dupilumab. (Pubmed Central) - Mar 3, 2023
Increased understanding of the local immunologic dysfunction has led to several therapeutics that can potentially restore epithelial barrier function and olfaction. Real world and comparative effectiveness studies are needed.
- || Review, Journal: Response to monoclonal antibodies in asthma: definitions, potential reasons for failure and therapeutic options for suboptimal response. (Pubmed Central) - Feb 27, 2023
Real world and comparative effectiveness studies are needed. No abstract available
- || Review, Journal: Efficacy of biologic therapy on airway hyperresponsiveness in asthma. (Pubmed Central) - Feb 26, 2023
In contrast, there have comparatively been fewer studies investigating the efficacy of biologics in AHR. In this focussed review, we summarise the existing evidence base in this area in regard to omalizumab, mepolizumab, benralizumab, tralokinumab and tezepelumab.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New P2 trial: Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma (clinicaltrials.gov) - Feb 23, 2023
P2, N=34, Not yet recruiting, Sponsor: McMaster University
- |||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New trial: TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS) (clinicaltrials.gov) - Feb 15, 2023
P=N/A, N=400, Not yet recruiting, Sponsor: AstraZeneca
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment open: UPSTREAM-COPD: Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD (clinicaltrials.gov) - Feb 8, 2023
P2, N=80, Recruiting, Sponsor: Asger Sverrild
In this focussed review, we summarise the existing evidence base in this area in regard to omalizumab, mepolizumab, benralizumab, tralokinumab and tezepelumab. Not yet recruiting --> Recruiting
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab Reduces Exacerbations Across All Seasons In Patients With Severe, Uncontrolled Asthma With Seasonal Allergy: Results From The Phase 3 NAVIGATOR Study (Convention Center, Ballroom Level, Hemisfair C1) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_2105;
P3
Not yet recruiting --> Recruiting Tezepelumab reduced exacerbations during the relevant seasons, consistent with its mechanism targeting TSLP in the airway epithelium.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
TEZSPIRE: A Shift in Perspective (Grand Hyatt, Fourth Floor, Texas A) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_2066;
Sponsored by Amgen and AstraZeneca Please join Amgen and AstraZeneca to learn about a new option that may change your perspective. Our experts will share the efficacy and safety data around a different approach.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Effect Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Age Of Onset, Allergic Status, And Eosinophilic Phenotype (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1704;
P2, P3
Our experts will share the efficacy and safety data around a different approach. Tezepelumab reduced exacerbations versus placebo in a broad population of patients with severe, uncontrolled asthma grouped by age of onset and inflammatory phenotype.
- Comparative Efficacy of Tezepelumab, Mepolizumab, Benralizumab, and Dupilumab in Eosinophilic Asthma: A Bayesian Network Meta-analysis (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1701;
Tezepelumab reduced exacerbations versus placebo in a broad population of patients with severe, uncontrolled asthma grouped by age of onset and inflammatory phenotype. In individuals with asthma and eosinophils ?300 cells/
- Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1699;
About 4.66% of individuals in studies of biologics in asthma developed ADAs over the follow up period. The incidence of ADA was highest in benralizumab studies and lowest in the omalizumab studies.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Early experience with the anti-TSLP monoclonal antibody tezepelumab-ekko (Tezspire) in type 2 asthma () - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1279;
We describe three adult patients with severe persistent TH2 driven asthma which were not controlled with maximal inhaled and oral therapy as well as multiple biologic agents. In all three cases, treatment with tezepelumab alone or in combination with a second biologic led to significant improvement in both subjective and objective measures of inflammation and lung function, suggesting that telepezumab should be considered even where multiple biologics have not previously achieved control.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab-ekko Improved Asthma Control and Asthma Symptom in Adults with Uncontrolled and Severe Asthma in Real-Life (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1206;
In all three cases, treatment with tezepelumab alone or in combination with a second biologic led to significant improvement in both subjective and objective measures of inflammation and lung function, suggesting that telepezumab should be considered even where multiple biologics have not previously achieved control. Over the 6-months period, Tezepelumab-ekko showed reduction in asthma exacerbations and steroid bursts, and improved asthma control and symptoms in patients with uncontrolled asthma.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Efficacy Of Tezepelumab In Patients With Severe, Uncontrolled Asthma By Specific Perennial Allergen Immunoglobulin E Thresholds (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1202;
P2, P3
Over the 6-months period, Tezepelumab-ekko showed reduction in asthma exacerbations and steroid bursts, and improved asthma control and symptoms in patients with uncontrolled asthma. Tezepelumab, versus placebo, consistently reduced exacerbations in patients with severe, uncontrolled allergic asthma, irrespective of high or low IgE threshold.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab Efficacy By SNOT-22 Score In Patients With Severe, Uncontrolled Asthma And Comorbid Nasal Polyps In NAVIGATOR (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1201;
P3
Tezepelumab, versus placebo, consistently reduced exacerbations in patients with severe, uncontrolled allergic asthma, irrespective of high or low IgE threshold. Tezepelumab provided clinically meaningful improvements in rhinosinusitis symptoms over 52 weeks versus placebo in patients with severe, uncontrolled asthma and remote or recent history of comorbid NP.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Incidence Of Infections In Patients With Severe, Uncontrolled Asthma Treated With Tezepelumab: A Pooled Analysis Of The Phase 2b PATHWAY And Phase 3 NAVIGATOR Studies (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1200;
P2, P3
The incidence of infection-related AEs was similar between the tezepelumab and placebo groups. Tezepelumab treatment did not lead to an increased risk of infection.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Effect Of Tezepelumab On Rescue Medication Use And Night-Time Awakenings In Patients With Severe, Uncontrolled Asthma: Results From The NAVIGATOR Study (Convention Center, Lobby Level, Hall 2) - Feb 4, 2023 - Abstract #AAAAI2023AAAAI_1198;
P3
Tezepelumab treatment did not lead to an increased risk of infection. Adults and adolescents with severe, uncontrolled asthma receiving tezepelumab reported fewer uses of rescue medication and had fewer days with night-time awakenings over 52 weeks than those receiving placebo.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, lirentelimab (AK002) / Allakos
Journal: Allergology: what's new in 2022 (Pubmed Central) - Feb 2, 2023
In severe asthma, tezepelumab (human monoclonal antibody) reduces the annual asthma exacerbation rate over 52 weeks. In terms of diet, the new EAACI guidelines recommend avoiding cow's milk supplementation in infants during the first three days of life to reduce the risk of cow's milk allergy.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
$AMGN TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN https://t.co/aocM1aO9sr (Twitter) - Feb 2, 2023
- | Journal: Current and future management of chronic spontaneous urticaria and chronic inducible urticaria. (Pubmed Central) - Feb 1, 2023
Novel therapies are needed for the treatment of recalcitrant CU. With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU.
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment closed: COURSE: Tezepelumab COPD Exacerbation Study (clinicaltrials.gov) - Feb 1, 2023
P2a, N=335, Active, not recruiting, Sponsor: AstraZeneca
With a deeper understanding of the pathophysiology of CU, promising therapeutics are in clinical trials for CU. Recruiting --> Active, not recruiting
- || Retrospective data, Review, Journal: Incidence of Anti-Drug Antibodies to Monoclonal Antibodies in Asthma: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jan 31, 2023
The incidence was highest in the benralizumab group and lowest in the omalizumab group. The subcutaneous route and longer dosing intervals were associated with higher ADA development.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Is tezepelumab the ubiquitous biologic for severe asthma? (Pubmed Central) - Jan 27, 2023
The subcutaneous route and longer dosing intervals were associated with higher ADA development. No abstract available
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. (Pubmed Central) - Jan 27, 2023
P3
Tezepelumab treatment was well tolerated for up to 2 years and resulted in sustained, clinically meaningful reductions in asthma exacerbations in individuals with severe, uncontrolled asthma. These findings are consistent with previous randomised, placebo-controlled studies and show the long-term safety and sustained efficacy of tezepelumab in individuals with severe, uncontrolled asthma.
- || Review, Journal: Risks and safety of biologics: A practical guide for allergists. (Pubmed Central) - Jan 26, 2023
Our review focuses on the risk of hypersensitivity reactions, pregnancy-specific considerations, risk of infection and risk of malignancy. We also highlight drug-specific adverse events and unique safety issues identified in case reports.
- ||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Clinical: 🔥🔥Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study 🫁🏅📚🎯 https://t.co/W4wGa9cakb @DrMMukherjee @simcouillard @banavarrete @QuirceSantiago @ngpdoc @Hananianick @CPorsbjerg (Twitter) - Jan 26, 2023
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Is tezepelumab the ubiquitous biologic for severe asthma? https://t.co/E7IExLqKpI @doclip1 @DrCindyThamrin @DrMMukherjee @simcouillard @banavarrete @QuirceSantiago @ngpdoc @Hananianick @IanPavord @DocdelOlmo @ArchBronconeumo @CPorsbjerg @christinej200 @InigoOjanguren (Twitter) - Jan 25, 2023
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
🫁 #Asma| Tezepelumab está aprobado actualmente para el tratamiento del asma grave en EEUU, la UE, Japón y otros países @AstraZenecaES @EMA_News @ComisionEuropea @IanPavord @MenePangalos #medicamentos https://t.co/nlAUWd1ZNI (Twitter) - Jan 25, 2023
- | Journal: Pharmacotherapy: New drugs and vaccines in 2022 (Pubmed Central) - Jan 21, 2023
Eptinezumab: another anti-CGRP antibody for the prevention of migraine. Ponesimod: multiple sclerosis treatment with the advantage of a shorter half-life than fingolimod or ozanimod.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma. (Pubmed Central) - Jan 20, 2023
It is proposed that the focus should be on single attribute measures of the latent construct "need fulfillment quality of life". These measures would meet the required standards of Rasch Measurement Theory (RMT) applying simultaneous conjoint standards of measurement theory, as well as capturing the patient voice.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Enrollment open, Trial initiation date: Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma (clinicaltrials.gov) - Jan 20, 2023
P3, N=30, Recruiting, Sponsor: McMaster University
These measures would meet the required standards of Rasch Measurement Theory (RMT) applying simultaneous conjoint standards of measurement theory, as well as capturing the patient voice. Not yet recruiting --> Recruiting | Initiation date: May 2022 --> Nov 2022
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Tezepelumab for asthma. (Pubmed Central) - Jan 19, 2023
In this regard, tezepelumab (AMG-157/MEDI-9929), a TSLP-targeted first-in-class fully human monoclonal antibody, has been shown in phase II and III studies to be effective and safe in treating patients with severe asthma, regardless of the underlying endotype or phenotype and irrespective of baseline biomarkers, such as blood eosinophil count and fraction of exhaled nitric oxide. Here, we provide a comprehensive review of TSLP function in airway inflammatory processes, the clinical development of tezepelumab for severe asthma as well as its possible future indications.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezspire approved for self-administration in the EU in a new pre-filled pen https://t.co/a24Bq7Y1y2 (Twitter) - Jan 12, 2023